Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yvette Kasamon

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Hospital Medicine|April 16, 2010
Self-medication and intractable coughMatthew C Stewart, Yvette Kasamon
The Lancet. Oncology|April 17, 2022
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpointNicholas C Richardson, Yvette Kasamon, Richard Pazdur, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 2009
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumorsRichard L Wahl, Heather Jacene, Yvette Kasamon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall SurvivalMargret Merino, Yvette Kasamon, Marc Theoret, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2013
Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphomaRobert F Hobbs, Richard L Wahl, Eric C Frey, et al.
Leukemia & Lymphoma|August 20, 2011
Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemiaDouglas E Gladstone, Lode Swinnen, Yvette Kasamon, et al.
Clinical Immunology (Orlando, Fla.)|June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokineticsCarla Casulo, Julie M Vose, William Y Ho, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2012
The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemiaDouglas E Gladstone, Amanda Blackford, Eunpi Cho, et al.
Leukemia & Lymphoma|August 1, 2012
Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcomaAmer Zeidan, Javier Bolaños-Meade, Yvette Kasamon, et al.
Pediatric Blood & Cancer|May 13, 2022
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphomaMargret Merino, Yvette Kasamon, Hongshan Li, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Hospital Medicine|April 16, 2010
Self-medication and intractable coughMatthew C Stewart, Yvette Kasamon
The Lancet. Oncology|April 17, 2022
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpointNicholas C Richardson, Yvette Kasamon, Richard Pazdur, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 2009
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumorsRichard L Wahl, Heather Jacene, Yvette Kasamon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall SurvivalMargret Merino, Yvette Kasamon, Marc Theoret, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2013
Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphomaRobert F Hobbs, Richard L Wahl, Eric C Frey, et al.
Leukemia & Lymphoma|August 20, 2011
Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemiaDouglas E Gladstone, Lode Swinnen, Yvette Kasamon, et al.
Clinical Immunology (Orlando, Fla.)|June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokineticsCarla Casulo, Julie M Vose, William Y Ho, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2012
The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemiaDouglas E Gladstone, Amanda Blackford, Eunpi Cho, et al.
Leukemia & Lymphoma|August 1, 2012
Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcomaAmer Zeidan, Javier Bolaños-Meade, Yvette Kasamon, et al.
Pediatric Blood & Cancer|May 13, 2022
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphomaMargret Merino, Yvette Kasamon, Hongshan Li, et al.
Pageof 2